The Conspiracy Against The Treatment of Cancer

26 November 2003







About Eve Hillary

Eve Hillary is based in Sydney. She is a medical analyst and writer
on issues pertaining to the health care industry and environmental
She is the author of `Children of a Toxic Harvest: An Environmental
Autobiography', and numerous articles relating to health issues. Her
most recent book is `Health Betrayal; Staying away from the sickness
industry'. She is also a public speaker.
Eve has spent 25 years in health care where she has observed the
medical industry at first hand from the inside.


The following section contains:

Source materials for further study
Websites for further information
References for professionals

Chemotherapy quotes
Cancer chemotherapy
"Two to 4% of cancers respond to chemotherapy..The bottom line is for
a few kinds of cancer chemo is a life extending procedure- Hodgkin's
disease, Acute Lymphocytic Leukemia (ALL), Testicular cancer, and
Choriocarcinoma."-Ralph Moss, Ph.D. 1995 Author of Questioning
NCI now actually anticipates further increases, and not decreases,
in cancer mortality rates, from 171/100,000 in 1984 to 175/100,000 by
the year 2000!"-Samuel Epstein.
A study of over 10,000 patients shows clearly that chemo's
supposedly strong track record with Hodgkin's disease (lymphoma) is
actually a lie. Patients who underwent chemo were 14 times more
likely to develop leukemia and 6 times more likely to develop cancers
of the bones, joints, and soft tissues than those patients who did
not undergo chemotherapy (NCI Journal 87:10)."-John Diamond
Children who are successfully treated for Hodgkin's disease are 18
times more likely later to develop secondary malignant tumours. Girls
face a 35 per cent chance of developing breast cancer by the time
they are 40-which is 75 times greater than the average. The risk of
leukemia increased markedly four years after the ending of successful
treatment, and reached a plateau after 14 years, but the risk of
developing solid tumours remained high and approached 30 per cent at
30 years (New Eng J Med, March 21, 1996)
"Success of most chemotherapy is appalling.There is no scientific
evidence for its ability to extend in any appreciable way the lives
of patients suffering from the most common organic cancer.
chemotherapy for malignancies too advanced for surgery which accounts
for 80% of all cancers is a scientific wasteland."-Dr Ulrich Abel.
The New England Journal of Medicine Reports- War on Cancer Is a
Failure: Despite $30 billion spent on research and treatments since
1970, cancer remains "undefeated," with a death rate not lower but 6%
higher in 1997 than 1970, stated John C. Bailar III, M.D., Ph.D., and
Heather L. Gornik, M.H.S., both of the Department of Health Studies
at the University of Chicago in Illinois. "The war against cancer is
far from over," stated Dr. Bailar. "The effect of new treatments for
cancer on mortality has been largely disappointing."
"My studies have proved conclusively that untreated cancer victims
live up to four times longer than treated individuals. If one has
cancer and opts to do nothing at all, he will live longer and feel
better than if he undergoes radiation, chemotherapy or surgery, other
than when used in immediate life-threatening situations."-Prof Jones.
(1956 Transactions of the N.Y. Academy of Medical Sciences, vol 6.)
In a fifty page article by Hardin Jones of National Cancer Institute
of Bethesda, Maryland, he surveyed global cancer of all types and
compared the untreated and the treated, to conclude that the
untreated outlive the treated, both in terms of quality and in terms
of quantity.
"With some cancers, notably liver, lung, pancreas, bone and advanced
breast, our 5 year survival from traditional therapy alone is
virtually the same as it was 30 years ago."-P Quillin, Ph.D.
"1.7% increase in terms of success rate a year, it's nothing. By the
time we get to the 24 century we might have effective treatments,
Star Trek will be long gone by that time." Ralph Moss.
"..chemotherapy's success record is dismal. It can achieve remissions
in about 7% of all human cancers; for an additional 15% of cases,
survival can be "prolonged" beyond the point at which death would be
expected without treatment. This type of survival is not the same as
a cure or even restored quality of life."-John Diamond, M.D.
"Keep in mind that the 5 year mark is still used as the official
guideline for "cure" by mainstream oncologists. Statistically, the 5
year cure makes chemotherapy look good for certain kinds of cancer,
but when you follow cancer patients beyond 5 years, the reality often
shifts in a dramatic way."-Dr. John Diamond MD
"Most cancer patients in this country die of chemotherapy.
Chemotherapy does not eliminate breast, colon or lung cancers. This
fact has been documented for over a decade. Yet doctors still use
chemotherapy for these tumours.Women with breast cancer are likely to
die faster with chemo than without it."-Alan Levin, M.D.
"The five year cancer survival statistics of the American Cancer
Society are very misleading. They now count things that are not
cancer, and, because we are able to diagnose at an earlier stage of
the disease, patients falsely appear to live longer. Our whole cancer
research in the past 20 years has been a failure. More people over 30
are dying from cancer than ever before.More women with mild or benign
diseases are being included in statistics and reported as
being "cured". When government officials point to survival figures
and say they are winning the war against cancer they are using those
survival rates improperly."-Dr J. Bailer, New England Journal of
Medicine (Dr Bailer's answer to questions put by Neal Barnard MD of
the Physicians Committee For Responsible Medicine and published in
PCRM Update, Sept/Oct 1990.)
"I look upon cancer in the same way that I look upon heart disease,
arthritis, high blood pressure, or even obesity, for that matter, in
that by dramatically strengthening the body's immune system through
diet, nutritional supplements, and exercise, the body can rid itself
of the cancer, just as it does in other degenerative diseases.
Consequently, I wouldn't have chemotherapy and radiation because I'm
not interested in therapies that cripple the immune system, and, in
my opinion, virtually ensure failure for the majority of cancer
patients."-Dr Julian Whitaker, M.D.
"Finding a cure for cancer is absolutely contraindicated by the
profits of the cancer industry's chemotherapy, radiation, and surgery
cash trough."
-Dr Diamond, M.D.
"We have a multi-billion dollar industry that is killing people,
right and left, just for financial gain. Their idea of research is to
see whether two doses of this poison is better than three doses of
that poison."-Glen Warner, M.D. oncologist.
John Robbins:
 "Percentage of cancer patients whose lives are predictably saved b=
chemotherapy - 3%
 Conclusive evidence (majority of cancers) that chemotherapy has an=
positive influence on survival or quality of life - none.
 Percentage of oncologists who said if they had cancer they would
not participate in chemotherapy trials due to its "ineffectiveness
and its unacceptable toxicity" - 75%
 Percentage of people with cancer in the U.S. who receive
chemotherapy - 75%.
 Company that accounts for nearly half of the chemotherapy sales in=
the world - Bristol-Meyers Squibb.
 Chairman of the board of Bristol-Meyers - Richard L. Gelb.
 Mr. Gelb's other job: vice chairman, board of overseers, board of =

managers, Memorial Sloan-Kettering Cancer Center, World's largest
private cancer treatment and research center.
 Chairman, Memorial Sloan-Kettering's board of overseers, board of =

managers - John S. Reed.
 Reed's other job - director, Philip Morris (tobacco company).
 Director, Ivax, Inc., a prominent chemotherapy company - Samuel

 Broder's other job (until 1995) - executive director, National
Cancer Institute.
From "Reclaiming Our Health: Exploding the Medical Myth and Embracing
the Source of True Healing" by John Robbins.
"If you can shrink the tumour 50% or more for 28 days you have got
the FDA's definition of an active drug. That is called a response
rate, so you have a response...(but) when you look to see if there is
any life prolongation from taking this treatment what you find is all
kinds of hocus pocus and song and dance about the disease free
survival, and this and that. In the end there is no proof that
chemotherapy in the vast majority of cases actually extends life, and
this is the GREAT LIE about chemotherapy, that somehow there is a
correlation between shrinking a tumour and extending the life of the
patient."-Ralph Moss
"The majority of publications equate the effect of chemotherapy with
(tumour) response, irrespective of survival. Many oncologists take it
for granted that response to therapy prolongs survival, an opinion
which is based on a fallacy and which is not supported by clinical
studies. To date there is no clear evidence that the treated
patients, as a whole, benefit from chemotherapy as to their quality
of life."-Abel.1990.
For the majority of the cancers we examined, the actual improvements
(in survival) have been small or have been overestimated by the
published rates...It is difficult to find that there has been much
progress...(For breast cancer), there is a slight improvement...
(which) is considerably less than reported."-U.S. Federal Government
General Accounting Office
"As a chemist trained to interpret data, it is incomprehensible to me
that physicians can ignore the clear evidence that chemotherapy does
much, much more harm than good."-Alan Nixon, Ph.D., Past President,
American Chemical Society.
He said, "I'm giving cancer patients over here at this major cancer
clinic drugs that are killing them, and I can't stop it because they
say the protocol's what's important." And I say, "But the patient's
not doing well." They say, "The protocol's what's important, not the
patient." And he said, "You can't believe what goes on in the name of
medicine and science in this country." -Gary Null
The Politics of Cancer- Professor Emeritus Dr. Samuel Epstein
That in spite of over $20 billion expenditures since the "War against
Cancer" was launched by President Nixon in 1971, there has been
little if any significant improvement in treatment and survival rates
for most common cancers, in spite of contrary misleading hype by the
cancer establishment-the National Cancer Institute (NCI) and American
Cancer Society (ACS).
That the cancer establishment remains myopically fixated on damage
control - diagnosis and treatment - and basic genetic research, with,
not always benign, indifference to cancer prevention. Meanwhile, the
incidence of cancer, including nonsmoking cancers, has escalated to
epidemic proportions with lifetime cancer risks now approaching 50%.
That the NCI has a long track record of budgetary shell games in
efforts to mislead Congress and the public with its claim that it
allocates substantial resources to cancer prevention. Over the last
year, the NCI has made a series of widely divergent claims, ranging
from $480 million to $1 billion, for its prevention budget while
realistic estimates are well under $100 million.
That the NCI allocates less than 1% of its budget to research on
occupational cancer the most avoidable of all cancers which accounts
for well over 10% of all adult cancer deaths, besides being a major
cause of childhood cancer.
That cancer establishment policies, particularly those of the ACS,
are strongly influenced by pervasive conflicts of interest with the
cancer drug and other industries. As admitted by former NCI director
Samuel Broder, the NCI has become "what amounts to a governmental
pharmaceutical company".
That the MD Anderson Comprehensive Cancer Center was sued in August,
1998, for making unsubstantiated claims that it cures "well over 50%
of people with cancer".
That the NCI, with enthusiastic support from the ACS, the tail that
wags the NCI dog, has effectively blocked funding for research and
clinical trials on promising non-toxic alternative cancer drugs for
decades, in favor of highly toxic and largely ineffective patented
drugs developed by the multibillion dollar global cancer drug
industry. Additionally, the cancer establishment has systematically
harassed the proponents of non-toxic alternative cancer drugs.
That, as reported in The Chronicle of Philanthropy, the ACS is "more
interested in accumulating wealth than saving lives". Furthermore, it
is the only known "charity" that makes contributions to political
That the NCI and ACS have embarked on unethical trials with two
hormonal drugs, Tamoxifen and Evista, in ill-conceived attempts to
prevent breast cancer in healthy women while suppressing evidence
that these drugs are known to cause liver and ovarian cancer,
respectively, and in spite of the short-term lethal complications of
Tamoxifen. The establishment also proposes further chemoprevention
trials this fall on Tamoxifen, and also Evista, in spite of two
published long-term European studies on the ineffectiveness of
Tamoxifen. This represents medical malpractice verging on the
That the ACS and NCI have failed to provide Congress and regulatory
agencies with available scientific information on a wide range of
unwitting exposures to avoidable carcinogens in air, water, the
workplace, and consumer products food, cosmetics and toiletries, and
household products. As a result, corrective legislative and
regulatory action has not been taken.
That the cancer establishment has also failed to provide the public,
particularly African American and underprivileged ethnic groups with
their disproportionately higher cancer incidence rates, with
information on avoidable carcinogenic exposures, thus depriving them
of their right-to-know and effectively preventing them from taking
action to protect themselves - a flagrant denial of environmental
justice Cancer Inormation and Support Society Sydney, Aust. Integrated cancer hospital.
According to the National Cancer Institute, about one-third of all
cancer deaths are related to malnutrition. For cancer patients,
optimal nutrition is important. Cancer can deplete your body's
nutrients and cause weight loss. Cancer and cancer treatment can also
have a negative effect on your appetite, and your body's ability to
digest foods. These factors may leave you in a vulnerable condition -
high nutrient need, and low nutrient intake.
At Cancer Treatment Centers of America, we believe that nutrition
plays an important role in the treatment of cancer. That's why each
patient who comes to us for help receives a nutrition assessment and
an individualized plan designed to prevent malnutrition, reduce side
effects and enhance his or her overall well being. Cancer Treatment
Centres of
America. Database on natural cancer therapies
for health professionals.
Pay site.


Einhorn, J., Nitrogen mustard: the origin of chemotherapy for
cancer, Int. J. Radiat. Oncol. Biol. Phys., 1985, 11(7), 1375-1378.
2. Goodman, L. S.; Wintrobe, M. M.; Dameshek, W.; Goodman, M. J.;
Gilman, A.; McLennan, M. T., Landmark article Sept. 21, 1946:
Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine
hydrochloride and tris(beta-chloroethyl)amine hydrochloride for
Hodgkin's disease, lymphosarcoma, leukemia and certain allied and
miscellaneous disorders. J. Am. Med. Assoc., 1984, 251(17), 2255-
3. Delayed Administration of Sodium Thiosulfate in Animal Models
Reduces Platinum Ototoxicity without Reduction of Antitumor Activity
Leslie L. Muldoon, Michael A. Pagel, Robert A. Kroll, Robert E.
Brummett, Nancy D. Doolittle, Eleanor G. Zuhowski, Merrill J. Egorin
and Edward A. Neuwelt

4. In an especially dramatic table, Dr. Abel displays the results of
chemotherapy in patients with various types of cancers, as the
improvement of survival rates, compared to untreated patients. This
table shows:
a In colorectal cancer: no evidence survival is improved.
b.Gastric cancer: no clear evidence.
c.Pancreatic cancer: Study completely negative. Longer survival in
control (untreated) group.[emphasis mine:rsc]
d.Bladder: no clinical trial done.
e.Breast cancer: No direct evidence that chemotherapy prolongs
survival; its use is "ethically questionable." (That is particularly
newsworthy, since all breast cancer patients, before or after
surgery, are given chemotherapy drugs.)
f.Ovarian cancer: no direct evidence.
g.Cervix and uterus: No improved survival.
h. Head and neck: no survival benefit but occasional shrinkage of
5. Sankila, Risto, et al. "Risk of cancer among offspring of
childhood cancer survivors." New England Journal of Medicine 338, no.
19 (1998): 1339-44.
6.Sklar, C.A. "Growth and neuroendocrine dysfunction following
therapy for childhood cancer." Pediatric Clinics of North America 44
(1997): 489-503.
7. Wallace, W.H., and C.J. Kelnar. "Late effects of antineoplastic
therapy in childhood on growth and endocrine function."
Drug Safety
15, no. 5 (Nov 1996): 325-32.
8. Sklar, C.A. "Growth and neuroendocrine dysfunction following
therapy for childhood cancer." Pediatric Clinics of North America 44
(1997): 489-503.
9. Wallace, W.H., and C.J. Kelnar. "Late effects of antineoplastic
therapy in childhood on growth and endocrine function."
Drug Safety
15, no. 5 (Nov 1996): 325-32.
10. Goldiner, P.L., and O. Schweizer. "The hazards of anesthesia and
surgery in bleomycin-treated patients."
Seminars in Oncology 6, no. 1
(Mar 1979): 121-4.
11. Hulbert, J.C., J.E. Grossman, and K.B. Cummings. "Risk factors of
anesthesia and surgery in bleomycin-treated patients."
Journal of
Urology 130, no. 1 (Jul 1983): 163-4.
12. Miller, R.W., et al. "Pulmonary function abnormalities in long-
term survivors of childhood cancer." Medical Pediatric Oncology 14,
no. 4 (1986): 202-7.
13. Farrell, G.C. "Drug-induced hepatic injury." Journal of
Gastroenterology and Hepatology 12, no. 9-10 (Oct 1997): S242-50.
14. Aisenberg, J., et al. "Bone mineral density in young adult
survivors of childhood cancer." Journal of Pediatrics
Hematology/Oncology 20, no. 3 (May-Jun 1998): 241-5.
15. Arikoski, P., et al. "Reduced bone mineral density in long-term
survivors of childhood acute lymphoblastic leukemia." Journal of
Pediatrics Hematology/Oncology 20, no. 3 (May 1998): 234-240.
16. Halton, J.M., et al. "Altered mineral metabolism and bone mass in
children during treatment for acute lymphoblastic leukemia." Journal
of Bone Mineral Research 11, no. 11 (Nov 1996): 1774-83.
17. Hanif, I., H. Mahmoud, and C.H. Pui. "Avascular femoral head
necrosis in pediatric cancer patients."
Medical Pediatric Oncology
21, no. 9 (1993): 655-60.
18. Henderson, R.C., C.D. Madsen, C. Davis, and S.H. Gold. "Bone
density in survivors of childhood malignancies."
Journal of
Pediatrics Hematology/Oncology 18, no. 4 (Nov 1996): 367-71.
19. Henderson, R.C., et al. "Longitudinal evaluation of bone mineral
density in children receiving chemotherapy." Journal of Pediatrics
Hematology/Oncology 20, no. 4 (Jul-Aug 1998): 322-6.
20. Hesseling, P.B., et al. "Bone mineral density in long-term
survivors of childhood cancer." International Journal of Cancer 11
Supplement (1998): 44-7.
21. Hoorweg-Nijman, J.J., et al. "Bone mineral density and markers of
bone turnover in young adult survivors of childhood lymphoblastic
leukaemia." Clinical Endocrinology (Oxford) 50, no. 2 (Feb 1999): 237-
22. Muller, H.L., M. Klinkhammer-Schalke, and J. Kuhl. "Final height
and weight of long-term survivors of childhood malignancies."

Experimental and Clinical Endocrinology and Diabetes 106, no. 2
(1998): 135-9.
23. Talvensaari, K., and M. Knip. "Childhood cancer and later
development of the metabolic syndrome."
Annals of Medicine 29, no. 5
(Oct 1997): 353-5.
24. Talvensaari, K., et al. "Clinical characteristics and factors
affecting growth in long-term survivors of cancer." Medical Pediatric
Oncology 26, no. 3 (Mar 1996): 166-72.
25. Mauch, P.M., et al. "Second malignancies after treatment for
laparotomy staged IA-IIIB Hodgkin's disease: a long-term analysis of
risk factors and outcome." Blood 87, no. 9 (1 May 1996): 3625-32.
26. Neglia, J.P., et al. "Second neoplasms after acute lymphoblastic
leukemia in childhood." New England Journal of Medicine 325, no. 19
(7 Nov 1991): 1330-6.
27. Nicholson, H.S., et al. "Late effects of therapy in adult
survivors of osteosarcoma and Ewing's sarcoma." Medical Pediatric
Oncology 20, no. 1 (1992): 6-12.
28. Novakovic, B., et al. "Late effects of therapy in survivors of
Ewing's sarcoma family tumors." Pediatric Hematology/Oncology 19, no.
3 (May-June 1997): 220-5.
29. Nyandoto, P., T. Muhonen, and H. Joensuu. "Second cancer among
long-term survivors from Hodgkin's disease."
International Journal of
Radiation Oncology and Biological Physics 42, no. 2 (1 Sept 1998):
30. Nygaard, R., et al. "Second malignant neoplasms in patients
treated for childhood leukemia. a population-based m cohort study
from the Nordic countries, The Nordic Society of Pediatric Oncology
and Hematology (NOPHO)." Acta Pediatrics Scandinavia 80, no. 12 (Dec
1991): 1220-8.
31. Pratt, C.B.B., et al. "Second malignant neoplasms occurring in
survivors of osteosarcoma." Cancer 80, no. 5 (1 Sept 1997): 960-5.
32. Rich, D.C., et al. "Second malignant neoplasms in children after
treatment of soft tissue sarcoma." Journal of Pediatrics Surgery 32,
no. 2 (Feb 1997): 369-72.
33. Robison, L.L. "Survivors of childhood cancer and risk of a second
tumor." Journal of the National Cancer Institute 85, no. 14 (21 Jul
): 1102-3.
34. Sankila, R., et al. "Risk of subsequent malignant neoplasms among
1,641 Hodgkin's disease patients diagnosed in childhood and
adolescence: a population-based cohort study in the five Nordic
countries. Association of the Nordic Cancer Registries and the Nordic
Society of Pediatric Hematology and Oncology."
Journal of Clinical
Oncology 14, no. 5 (May 1996): 1442-6.
35. Scaradavou, A. "Second malignant neoplasms in long-term survivors
of childhood rhabdomyosarcoma." Cancer 76, no. 10 (15 Nov 1995): 1860-
36. Witherspoon, R.P., H.J. Deeg, and R. Storb. "Secondary
malignancies after marrow transplantation for leukemia or aplastic
Transplantation Science 4, no. 1 (Sept 1994): 33-41.
37. Wolden, S.L., et al. "Second cancers following pediatric
Hodgkin's disease." Journal of Clinical Oncology 16, no. 2 (Feb
1998): 536-44.
38. Wong, F.L., et al. "Secondary brain tumors in children treated
for acute lymphoblastic leukemia at St. Jude Children's Research
." Journal of Clinical Oncology 16, no. 12 (Dec 1998): 3761-
39. Barakat, L.P., et al. "Families surviving childhood cancer: a
comparison of posttraumatic stress symptoms with families of healthy
children." Journal of Pediatric Psychology 22, no. 6 (1997): 843-59.
40. Gray, R.E. "Psychologic adaptation of survivors of childhood
cancer." Cancer 70, no. 11 (Dec 1992): 2713-21.
41. Greenberg, H.S., et al. "Psychologic functioning in 8-16-year-old
cancer survivors and their parents." Journal of Pediatrics 114, no. 3
(Mar 1989): 488-93.
42. Hollen, P.J., and W.L. Hobbie. "Risk taking and decision making
of adolescent long-term survivors of cancer."
Oncology Nursing Forum
17 (1994): 137-48.
43. Kazak, A.E., et al. "Posttraumatic stress, family functioning,
and social support in survivors of childhood leukemia and their
mothers and fathers." Journal of Consulting and Clinical Psychology
65 (1997): 120-9.
44. Kazak, A.E., et al. "Young adult cancer survivors and their
parents: adjustment, learning problems, and gender." Journal of
Family Psychology 8, no. 1 (1994): 74-84.
45. Lansky, S., et al. "Psychosocial consequences of cure." Cancer 58
(1986): 529-33.
46. Mulhern, R.K., et al. "Social competence and behavioral
adjustment of children who are long-term survivors of cancer."
Pediatrics 83 (1989): 18-25.
47. Stuber, M.L., et al. "Posttrauma symptoms in childhood leukemia
survivors and their parents." Psychosomatics 37, no. 3 (May-Jun
1996): 254-61.
48. Zeltzer, L.K., et al. "Comparison of psychologic outcomes in
adult survivors of childhood acute lymphoblastic leukemia versus
sibling controls: A cooperative Children's Cancer Group and National
Institutes of Health study." Journal of Clinical Oncology 15 (1997):
49. The chemicals used for chemotherapy are scheduled by the
government regulator (TGA) as Schedule 4 drugs (S4). The regulator
has placed antibiotics into the same category. Interestingly, the
mineral selenium, freely found in yeast and many other foods, has now
also been classed as a schedule 4 drug.

50 The key idea in orthomolecular medicine is that genetic factors
are central not only to the physical characteristics of individuals,
but also to their biochemical milieu. Biochemical pathways of the
body have significant genetic variability in terms of transcriptional
potential and individual enzyme concentrations, receptor-ligand
affinities and protein transporter efficiency. Diseases such as
atherosclerosis, cancer, schizophrenia or depression are associated
with specific biochemical abnormalities which are either causal or
aggravating factors of the illness. In the orthomolecular view, it is
possible that the provision of vitamins, amino acids, trace elements
or fatty acids in amounts sufficient to correct biochemical
abnormalities will be therapeutic in preventing or treating such

 Studies Relating to Chemotherapy

Knox RA. Response is slow to deadly mixups. Too little done to
avert cancer drug errors.
Boston Globe. June 26, 1995:29-33.
2. O'Donnell J. Hospital sued for not giving rescue agent. Hosp Pharm
Rep. 1993;7:29.
3. Cohen M, Anderson R, Attilio RM, et al. Preventing medication
errors in cancer chemotherapy. Am J Health Syst Pharm. 1996;53:737-
4. Koren G, Beatty K, Seto A, et al. The effects of impaired liver
function on the elimination of antineoplastic agents.
Pharmacother. 1992;26:363-371.
5. Calvert AH, Vewell DR, Gumbrell LA, et al. Carboplatin dosage:
prospective evaluation of a simple formula based on renal function. J
Clin Oncol.
6. Kintzel P, Dorr RT. Anticancer drug renal toxicity and
elimination: dosing guidelines for altered renal function. Cancer
Treat Rev. 1995;21:33-64.
7. AHFS Drug Information. American Society of Health-System
Pharmacists 1994-1998.
8. Ewer MS, Benjamin RS. Cardiotoxicity of chemotherapeutic drugs.
In: Perry MC, ed. The Chemotherapy Source Book. 2nd ed. Baltimore:
Williams & Wilkins; 1996:652.
9. Ginsberg SJ, Comis RL. The pulmonary toxicity of antineoplastic
In: Perry MC, Yarbro JW, eds. Toxicity of Chemotherapy.
Orlando, Fla: Grune and Stratton; 1984:227-268.
10. Patterson WP, Reams G. Renal and electrolyte abnormalities due to
chemotherapy. In: Perry MC, ed. The Chemotherapy Source Book. 2nd ed.
Baltimore: Williams & Wilkins; 1996:730-734.
11. Grochow BL, Ames MM. A Clinician's Guide to Chemotherapy
Pharmacokinetics and Pharmacodynamics.
Baltimore: Williams & Wilkins;
12. DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles & Practice
of Oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers;
13. Mitchelson F. Pharmacological agents affecting emesis: a review
(part I). Drugs. 1992;43:295-315.
14. Mitchelson F. Pharmacological agents affecting emesis: a review
(part II). Drugs. 1992;43:443-463.
15. Grunber SM, Hesketh PJ. Control of chemotherapy-induced emesis. N
Engl J Med. 1993;329:1790-1795.
16. Aapro MS. Review of experience with ondansetron and granisetron.
Ann Oncol. 1993;4(suppl 3):S9-S14.
17. Navari RM, Kaplan HG, Gralla RJ, et al. Efficacy and safety of
granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist,
in the prevention of nausea and vomiting induced by high-dose
cisplatin. J Clin Oncol. 1994;12:2204-2210.
18. Italian Group for Antiemetic Research. Dexamethasone,
granisetron, or both for the prevention of nausea and vomiting during
chemotherapy for cancer.
N Engl J Med. 1995;332:1-5.
19. Gralla RJ. Adverse effects of treatment. In: DeVita VT, Hellman
S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 4th
ed. Philadelphia: Lippincott-Raven Publishers; 1994:2338-2347.
20. American Society of Clinical Oncology. Recommendations for the
use of hematopoietic colony-stimulating factors: evidence-based
clinical practice guidelines. J Clin Oncol. 1994;12:2471-2508.
21. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol
and cisplatin.
A phase 1 and pharmacologic study. J Clin Oncol.
22. Balmer CM. Combination chemotherapy. In: Finley RS, Balmer CM,
Dozier N, et al, eds. Concepts in Oncology Therapeutics. A Self-
Instructional Course.
Bethesda, Md: American Society of Hospital
Pharmacists; 1991:102.
23. Browman GP. Clinical application of the concept of methotrexate
plus 5-FU sequence dependent synergy: how good is the evidence?
Cancer Treat Rep. 1984;68:465-469.
24. Koh DW, Castro M. Pulmonary toxicity of chemotherapeutic drugs.
In: Perry MC, ed. The Chemotherapy Source Book. 2nd ed. Baltimore:
Williams & Wilkins; 1996:674.
25. Ewer MS, Benjamin RS. Cardiotoxicity of chemotherapeutic drugs.
In: Perry MC, ed. The Chemotherapy Source Book. 2nd ed. Baltimore:
Williams & Wilkins; 1996:654.
26. Lindley CM, Bernard S, Fields SM. Incidence and duration of
chemotherapy-induced nausea and vomiting in the outpatient oncology
population. J Clin Oncol. 1989;7:1142-1149.
27. Gralla RJ, Navari RM, Hesketh PJ, et al. Single-dose oral
granisetron has equivalent antiemetic efficacy to intravenous
ondansetron for highly emetogenic cisplatin-based chemotherapy. J
Clin Oncol.
1998;16: 1568-1573.
28. Perez EA, Hesketh PJ, Sandbach J, et al. Comparison of single-
dose oral granisetron versus intravenous ondansetron in the
prevention of nausea and vomiting induced by moderately emetogenic
chemotherapy: a multicenter, double-blind, randomized parallel study.
J Clin Oncol. 1998;16:754-760.
29. Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed
vomiting: double-blind, randomized trial comparing placebo,
dexamethasone alone, and metoclopramide plus dexamethasone in
patients receiving cisplatin. J Clin Oncol. 1989;7:108-114.
30. Singh SS, Cartmell A, Caldwell J. Efficacy and tolerance of low
dose dexamethasone in combination with granisetron for prophylaxis of
emesis with high dose cisplatin containing chemotherapy. Int Pharm
Abstracts. 1998;35:2284.

------------------------ Yahoo! Groups Sponsor ---------------------~-->
Buy Ink Cartridges or Refill Kits for your HP, Epson, Canon or Lexmark
Printer at Free s/h on orders $50 or more to the US & Canada.

To unsubscribe from this group, send an email to:


Your use of Yahoo! Groups is subject to